CRITERION
From: The Australian
November 15, 2013 12:00AM
Regeneus (RGS) 37c
STILL on our furry friends, shares in the stem-cell play enjoyed a 9c, 32 per cent rocket yesterday after the recently listed entity won consent from US
veterinary gatekeepers to commercialise its novel canine cancer vaccine.
The remedy is derived from material from the ailing hound's own tumour or biopsy. The treatment has been tested on 40 dogs with life-threatening cancers.
Of these, 80 per cent survived for longer than they might have.
Regeneus' main game is treatments for human inflammatory ailments such as osteoarthritis. But is this one a case of the tail wagging the dog? Hold.
- See more at: http://www.theaustralian.com.au/business/opinion/greencross-a-
long-term-vet-as-it-dogs-big-guys/story-e6frg9lo-
1226760181440#sthash.VJVt8REy.dpuf
CRITERIONFrom: The AustralianNovember 15, 2013 12:00AMRegeneus...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
